Nothing Special   »   [go: up one dir, main page]

IN2014DN09228A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09228A
IN2014DN09228A IN9228DEN2014A IN2014DN09228A IN 2014DN09228 A IN2014DN09228 A IN 2014DN09228A IN 9228DEN2014 A IN9228DEN2014 A IN 9228DEN2014A IN 2014DN09228 A IN2014DN09228 A IN 2014DN09228A
Authority
IN
India
Prior art keywords
compounds
ews
ewing
tumors
compositions
Prior art date
Application number
Inventor
Jeffrey A Toretsky
Milton Lang Brown
Perrer N Tosso
Aykut Uren
Yali Kong
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of IN2014DN09228A publication Critical patent/IN2014DN09228A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds, compositions and methods relating to EWS-FLIl protein inhibitors are provided. The compounds have utility in the treatment of cancers including the Ewing's sarcoma family of tumors.
IN9228DEN2014 2012-04-12 2013-04-11 IN2014DN09228A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623349P 2012-04-12 2012-04-12
PCT/US2013/036234 WO2013155341A1 (en) 2012-04-12 2013-04-11 Methods and compositions for treating ewings sarcoma family of tumors

Publications (1)

Publication Number Publication Date
IN2014DN09228A true IN2014DN09228A (en) 2015-07-10

Family

ID=49328171

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9228DEN2014 IN2014DN09228A (en) 2012-04-12 2013-04-11

Country Status (13)

Country Link
US (2) US9290449B2 (en)
EP (1) EP2836481B1 (en)
JP (2) JP6130491B2 (en)
KR (1) KR102145835B1 (en)
CN (2) CN104395288B (en)
AU (2) AU2013245812B2 (en)
CA (1) CA2869513C (en)
HK (1) HK1207368A1 (en)
IL (1) IL234993B (en)
IN (1) IN2014DN09228A (en)
MX (1) MX2014011583A (en)
NZ (2) NZ700612A (en)
WO (1) WO2013155341A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
NZ700612A (en) 2012-04-12 2016-09-30 Univ Georgetown Methods and compositions for treating ewings sarcoma family of tumors
US9511050B2 (en) 2013-10-24 2016-12-06 Georgetown University Methods and compositions for treating cancer
CN111777596A (en) 2014-10-09 2020-10-16 英克特诺治疗公司 Indolone compounds and use thereof
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
US9895313B2 (en) 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
CN109219594B (en) 2016-03-31 2022-10-11 英克特诺治疗公司 Indoline analogue and application thereof
JP6885629B2 (en) * 2016-07-29 2021-06-16 オンターナル セラピューティック インコーポレイテッドＯｎｃｔｅｒｎａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Use of indolinone compounds
EP3558266B1 (en) 2016-12-21 2022-03-30 The Board of Regents of The University of Texas System Altertoxin ii as a selective inhibitor of ewing family of tumor cells
CN108186630B (en) * 2017-12-18 2020-07-31 温州医科大学 Application of isatin analogue in preparation of antitumor drugs
CN110870917B (en) * 2018-09-03 2022-03-15 上海市第一人民医院 Application of EWS or its up-regulator in preparing medicine for treating diabetes and preventing and treating diabetes individual tumorigenesis
US12076310B2 (en) * 2021-06-09 2024-09-03 University Of Rochester Compounds and methods for the treatment of acute myelogenous leukemia
CN114057626B (en) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) Indole-2, 3-dione derivative, preparation method thereof and anti-liver cancer drug for inhibiting RECQL4 specific expression
WO2023178040A2 (en) * 2022-03-13 2023-09-21 University Of Virginia Patent Foundation Inhibitors of ews-fli1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483704D1 (en) 1983-07-22 1991-01-17 Du Pont PHENYLQUINOLINE ACID AND DERIVATIVES AS AN ANTITUARY AGENT.
JP2002531498A (en) 1998-12-04 2002-09-24 ニューロサーチ、アクティーゼルスカブ Methods of using isatin derivatives as ion channel activators
CN1155572C (en) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 Indole derivatives and its anticancer usage
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
AU2005323437B2 (en) 2004-04-30 2011-10-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
AR056317A1 (en) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc OXINDOL COMPOUNDS AND PHARMACEUTICAL COMPOSITION
WO2006117414A1 (en) 2005-04-29 2006-11-09 Proyecto De Biomedicina Cima, S.L. Non-human animal sarcoma model
WO2008046083A2 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
EP2124910A4 (en) * 2006-12-29 2012-02-15 Univ Georgetown Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
PT2154966E (en) * 2007-04-20 2013-11-13 Univ New York State Res Found Benzimidazoles and pharmaceutical compositions thereof
US8377992B2 (en) * 2007-10-22 2013-02-19 The Wistar Institute TRBD-binding effectors and methods for using the same to modulate telomerase activity
WO2010083505A1 (en) 2009-01-19 2010-07-22 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
WO2012078519A2 (en) 2010-12-06 2012-06-14 Numerate, Inc. 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
NZ700612A (en) 2012-04-12 2016-09-30 Univ Georgetown Methods and compositions for treating ewings sarcoma family of tumors
CN103435606A (en) 2013-08-22 2013-12-11 中国药科大学 CDK2 and CSK3beta dual inhibitor and application thereof
US9511050B2 (en) 2013-10-24 2016-12-06 Georgetown University Methods and compositions for treating cancer
CN111777596A (en) 2014-10-09 2020-10-16 英克特诺治疗公司 Indolone compounds and use thereof

Also Published As

Publication number Publication date
US9714222B2 (en) 2017-07-25
CN107011242A (en) 2017-08-04
CA2869513A1 (en) 2013-10-17
CN107011242B (en) 2020-08-07
KR20150007311A (en) 2015-01-20
HK1207368A1 (en) 2016-01-29
CA2869513C (en) 2020-07-07
CN104395288B (en) 2016-12-14
JP2015512943A (en) 2015-04-30
WO2013155341A1 (en) 2013-10-17
NZ723971A (en) 2018-01-26
US20150051260A1 (en) 2015-02-19
JP2017141290A (en) 2017-08-17
NZ700612A (en) 2016-09-30
CN104395288A (en) 2015-03-04
IL234993B (en) 2019-02-28
AU2017201507A1 (en) 2017-03-23
US9290449B2 (en) 2016-03-22
EP2836481B1 (en) 2018-12-26
AU2017201507B2 (en) 2018-10-04
AU2013245812B2 (en) 2017-04-06
AU2013245812A2 (en) 2014-11-20
KR102145835B1 (en) 2020-08-20
JP6130491B2 (en) 2017-05-17
US20160159741A1 (en) 2016-06-09
MX2014011583A (en) 2016-02-09
AU2013245812A1 (en) 2014-11-13
EP2836481A1 (en) 2015-02-18
JP6345301B2 (en) 2018-06-20
EP2836481A4 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
IN2014DN09228A (en)
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2016004678A (en) Methods and compositions for treating cancer.
MX2020010535A (en) Methods of treating cancer.
MX366804B (en) R-spondin translocations and methods using the same.
MX2013004761A (en) Novel egfr-binding molecules and immunoconjugates thereof.
MX2016002544A (en) Compounds useful as immunomodulators.
UA109464C2 (en) Spiro-oxindoles as mdm2 antagonists
MY176489A (en) Novel tricyclic compounds as anticancer agents
MX2015014234A (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors.
MX2015005963A (en) Heterocyclic glutaminase inhibitors.
EA201590987A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2019008122A (en) Heterocycle amines and uses thereof.
MX357391B (en) Anti-erbb3 antibodies and uses thereof.
GB201106743D0 (en) Novel compounds
MX2015010125A (en) Pyridazinone-amides derivatives.
NZ744862A (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafenib
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
IN2014DN06104A (en)
NZ628433A (en) Chitosan-derived compositions
PH12015501088A1 (en) Dimeric compounds
MX2012013527A (en) Fused quinazoline derivatives and uses thereof.
MX2012012744A (en) Compositions and methods for the diagnosis and treatment of tumor.